Alphanine Market Report 2026

Alphanine Market Overview

• The Alphanine market growth in the historic period has been driven by high bleeding risk in hemophilia b, limited early treatment options • Market expansion is supported by expansion of prophylactic treatment protocols, increased patient life expectancy • Growth Driver: Rising Hemophilia Prevalence Boosts Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alphanine Market?

Alphanine is a clotting factor concentrate used primarily to treat hemophilia B, a bleeding disorder caused by a deficiency of factor IX. It is a plasma-derived product that helps to control and prevent bleeding episodes by replenishing the missing clotting factor in patients with hemophilia B is a highly purified, plasma-derived coagulation factor IX (FIX) concentrate used for the treatment of hemophilia B. The main formulations in the alphanine market are lyophilized powder and intravenous solutions. Lyophilized powder is a form of medication that has been freeze-dried to remove moisture, allowing for a longer shelf life and easier storage. The various disease indications include hemophilia A, hemophilia B, and hemophilia C, and several patient demographics including pediatrics, adults, and geriatric. The different distribution channels encompass hospitals, specialized clinics, retail pharmacies, and mail order pharmacies.

What Is The Alphanine Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of prophylactic treatment protocols, increased patient life expectancy, growth of home care infusion services, rising awareness of hemophilia management, improved reimbursement coverage. Major trends in the forecast period include rising demand for factor ix replacement, expansion of prophylactic hemophilia b therapy, increased use in surgical and trauma care, growing adoption of home infusion programs, strengthening of specialty treatment networks.

Global Alphanine Market Segmentation

1) By Formulation: Lyophilized Powder, Intravenous Solutions 2) By Disease Indication: Hemophilia A, Hemophilia B, Hemophilia C 3) By Patient Demographics: Pediatrics, Adults, Geriatric 4) By Distribution Channel: Hospitals, Specialized clinics, Retail Pharmacies, Mail Order Pharmacies

What Are The Drivers Of The Alphanine Market?

The rise in the prevalence of hemophilia is expected to propel the growth of the alphanine market going forward. Hemophilia is a rare, inherited bleeding disorder where the blood does not clot properly due to the absence or deficiency of certain clotting factors, viz. VIII and IX. The prevalence of hemophilia is rising due to factors such as improved diagnosis and awareness, better reporting and data collection, and genetic inheritance patterns. Alphanine helps in hemophilia by providing clotting factor VIII, which is essential for controlling bleeding and preventing hemorrhages in individuals with hemophilia A. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the rise in prevalence of hemophilia is driving the growth of the alphanine industry. The rising awareness of rare diseases is expected to propel the growth of the alphanine market going forward. Rare diseases are medical conditions that affect a small percentage of the population, often leading to challenges in diagnosis, treatment, and access to healthcare due to their low prevalence. The rising awareness of rare diseases is driven by increased media coverage, advocacy efforts, and advancements in diagnostics, which help improve early detection and access to specialized treatments for affected individuals. Alphanine plays a key role in the rising awareness of rare diseases by offering a targeted treatment for hemophilia, a rare bleeding disorder, which helps increase attention on both the disease and the need for effective therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, rising awareness of rare diseases drives the alphanine industry. Increase in the aging population is expected to propel the growth of the alphanine market going forward. An aging population refers to a demographic trend where the proportion of elderly individuals (usually defined as those aged 65 and older) in a population increases relative to other age groups. The aging population is a result of improved healthcare, better living conditions, and advancements in medical technology, leading to longer life expectancies and lower birth rates. Alphanine is used in the aging population to treat hemophilia and other bleeding disorders by providing clotting factor replacement to prevent or control bleeding episodes. For instance, in July 2024, according to the House of Commons Library, the UK-based library and information resource of the lower house of the British Parliament, in 2022, individuals aged 65 and over accounted for approximately 19% of the UK's population, totaling around 12.7 million people. By 2072, this demographic is projected to increase to 22.1 million, representing 27% of the population. Therefore, increase in the aging population drives the growth of the alphanine industry.

Key Players In The Global Alphanine Market

Major companies operating in the alphanine market are Grifols Biologicals Inc.

Regional Insights

North America was the largest region in the alphanine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Alphanine Market?

The alphanine market consists of sales of Factor IX concentrates, gene therapy solutions, and treatment regimens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alphanine Market Report 2026?

The alphanine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alphanine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.